Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Fresenius Medical Care heads into its November 3 quarterly results with a quiet but persistent tightening in bearish positioning, even as the borrow market itself remains comfortable.
The most notable development this week is the ORTEX short score, which has risen to 64.0, its highest reading in at least the past ten days. The climb has been steady, from 59.8 on September 23 to 64.0 today, a move that reflects a gradual accumulation of bearish signals rather than a sudden dislocation. Short interest at around 11% of the free float is meaningful, and the lending market confirms that short sellers are becoming more active. Availability has tightened sharply over the past month: the ratio of shares available to borrow against shares already borrowed has dropped from around 535% in early September to 321% now, the lowest reading in well over a month, though still far from stressed territory. Cost to borrow has drifted up a touch, around 0.80%, but remains firmly in "easy borrow" range. The picture is one of slowly building short pressure, not a crowded or squeezed trade.
The Street carries a modest upward lean. The analyst consensus mean price target is 41.69 EUR against a current price of 40.17 EUR, implying low single-digit upside. No analyst changes have been filed in the past two weeks. Factor scores tell a more textured story. The dividend score ranks in the 93rd percentile, the strongest pillar in the profile. The EV/EBIT valuation score sits at 81, confirming the stock trades at a discount relative to peers. But the outlook scores are weak: the 30-day EPS momentum ranks in just the 22nd percentile, the 12-month forward earnings growth rank is 21st, and the analyst recommendation score is near the bottom at 5th. The valuation is cheap by historical measures, with a trailing PE near 9.5x and price-to-book below 0.8x, but the earnings trajectory is not supporting a re-rating.
Alt data from the Centers for Medicare and Medicaid Services adds some texture. Medicaid units reimbursed for the company's drugs rose 71% year on year in Q1 2026, yet Medicaid dollars reimbursed fell 45% over the same period. That gap between volume and revenue points to significant per-unit price compression in the Medicaid channel, a dynamic consistent with the margin concerns that have weighed on the stock through 2026. Neither dataset carries a measured lead status, so neither should be read as a signal for the November print, they are colour on the operating environment, not a forecast.
The ownership structure is dominated by Fresenius SE, which holds just over 25% of shares. The most recent disclosed change was a reduction of roughly 16.6 million shares, though the last-reported date for that position is August 25. BlackRock added a modest 34,000 shares as recently as September 30. Insider activity is stale, the last recorded transaction was a routine grant in March 2026, and there has been no open-market buying or selling in the past six months.
Earnings history offers a sobering backdrop. The last three prints each produced a negative one-day move: roughly minus 3%, minus 7%, and minus 7% respectively, with the five-day windows also finishing in the red. The November 3 result is therefore not a setup where the market has historically rewarded the stock for delivering in line. The gap between the cheap valuation and the weak earnings momentum is the core tension to watch as the date approaches.
See the live data behind this article on ORTEX.
Open FME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
